Development of a novel peptide to prevent entry of SARS-CoV-2 into lung and olfactory bulb cells of hACE2 expressing mice.
Ping SuDongxu ZhaiAlbert H C WongFang LiuPublished in: Molecular brain (2022)
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a novel coronavirus that has caused a global pandemic Coronavirus Disease 2019 (COVID-19). Currently, there are no effective treatments specifically for COVID-19 infection. The initial step in SARS-CoV-2 infection is attachment to the angiotensin-converting enzyme 2 (ACE2) on the cell surface. We have developed a protein peptide that effectively disrupts the binding between the SARS-CoV-2 spike protein and ACE2. When delivered by nasal spray, our peptide prevents SARS-CoV-2 spike protein from entering lung and olfactory bulb cells of mice expressing human ACE2. Our peptide represents a potential novel treatment and prophylaxis against COVID-19.
Keyphrases
- sars cov
- respiratory syndrome coronavirus
- angiotensin converting enzyme
- coronavirus disease
- angiotensin ii
- induced apoptosis
- cell cycle arrest
- cell surface
- binding protein
- protein protein
- endothelial cells
- amino acid
- high fat diet induced
- wild type
- endoplasmic reticulum stress
- cell death
- small molecule
- metabolic syndrome
- transcription factor
- type diabetes
- human health
- induced pluripotent stem cells
- cell proliferation
- pi k akt
- combination therapy